We propose ABCB1 as an effective molecular target for carboplatin-resistant ovarian cancers harboring p53null mutations, which we uncovered could be used to increase the efficacy of conventional anti-cancer therapies, to develop more efficient combinatorial therapeutic interventions directed toward overcoming the chemoresistance and improving the survival rates in patients with ovarian cancer. The gene discussed is ABCB1; the disease is ovarian carcinoma.